Adjacent segment disease (ASD) is accelerated degeneration of spinal discs and joints above or below a prior surgical fusion, caused by mechanical stress the fused segment transfers to neighboring levels. It develops within 5–10 years in a subset of fusion patients and drives revision surgery — lumbar fusion revision rates exceed 20% within 10 years, with ASD a leading cause.

If you or someone you know has had spinal fusion and is now experiencing new or worsening back or leg pain, ASD is one of the first conditions your surgeon will evaluate. Understanding what ASD is — and why it happens — is essential context before deciding whether a second surgery is truly necessary. ValorSpine’s non-surgical spine treatment program is designed specifically for patients at this decision point.

This article explains ASD’s definition, the biomechanics behind it, how it is diagnosed, what treatment options exist — including structural biologics that address annular damage before another fusion is considered — and what questions to ask your care team.

Definition: What Adjacent Segment Disease Actually Means

Adjacent segment disease describes pathological changes — disc degeneration, facet arthritis, listhesis, herniation, or stenosis — that occur at the spinal level immediately next to a fused segment. The key word is disease: ASD is not simply normal aging at those levels. It is an accelerated process caused by altered mechanics.

Two related terms appear in the literature and are worth distinguishing:

• Adjacent segment degeneration (ASDeg): Radiographic changes visible on MRI or CT that are not yet producing symptoms. These changes are common; studies find radiographic evidence in a substantial proportion of patients within 5 years of fusion.
• Adjacent segment disease (ASD): The symptomatic subset — patients who have radiographic changes and new or worsening clinical symptoms attributable to the adjacent level.

The distinction matters clinically. Many fusion patients have some radiographic adjacent-level changes on imaging; far fewer have symptomatic ASD that warrants further intervention.

How Adjacent Segment Disease Develops: The Biomechanics of Fusion Stress Transfer

The spine is a kinetic chain. Each vertebral level contributes a share of flexion, extension, and rotation. When a surgeon fuses one or more levels with hardware and bone graft, motion at that segment is eliminated permanently. The spine compensates by distributing that lost motion to the segments above and below the fusion — primarily to the adjacent levels.

This redistribution produces three compounding effects:

1. Increased range of motion at adjacent levels: The adjacent disc and facet joints move through a larger arc with each step, bend, and lift than they would in an unfused spine. Over years, this cumulative over-motion accelerates wear.
2. Elevated intradiscal pressure: Biomechanical studies demonstrate measurably higher pressure in the disc immediately adjacent to a fusion construct during routine loading tasks.
3. Altered facet joint loading: The facet joints at the adjacent level bear greater compressive and shear forces, accelerating arthritic change and contributing to foraminal narrowing over time.

The net result, in susceptible patients, is that a disc that was marginally healthy before fusion — with some annular disruption or early dehydration — progresses to symptomatic herniation, stenosis, or instability within years rather than decades.

Why Adjacent Segment Disease Matters: The Revision Surgery Problem

ASD matters because its treatment trajectory often leads toward another fusion — extending the construct to the adjacent level — which simply shifts the stress problem one level higher or lower. This creates a documented cycle.

The data are clear: roughly 40% of back surgeries do not achieve the patient’s desired outcome, and revision surgery rates can exceed 20% within 10 years of lumbar fusion. A meaningful share of those revisions involve adjacent segment pathology.

The stakes are high for patients who receive an ASD diagnosis. Nearly 1 in 5 patients told they need spine surgery choose not to have it — and for ASD specifically, a growing body of research examines whether structural interventions at the disc level can stabilize adjacent-level degeneration before another fusion becomes necessary.

See our related analysis: Non-Surgical Spine Treatments Ranked by Evidence — which evaluates the evidence base for alternatives available at each stage of the degeneration spectrum.

Key Components: Risk Factors, Diagnosis, and Management

Adjacent Segment Disease Risk Factors and Management

Diagnosis

ASD is diagnosed through a combination of clinical presentation and imaging. Patients typically present with new axial pain, radiculopathy, or neurogenic claudication that did not exist immediately after their original fusion, or pain that resolved post-fusion and then returned at a different dermatomal pattern.

Standard workup includes:

• Standing AP and lateral X-rays (evaluate alignment, hardware integrity, listhesis)
• MRI of the lumbar spine with and without contrast if infection is a concern
• CT myelogram when MRI is contraindicated (metal artifact from hardware)
• Discography at the adjacent level if diagnosis is uncertain and intradiscal treatment is being considered

Treatment Options

Treatment follows a stepwise logic: conservative care before structural intervention, and structural intervention before extension fusion.

Conservative care (first line): Physical therapy focused on core stabilization and global movement patterns, anti-inflammatory medication management, and activity modification address symptoms in many patients with mild-to-moderate ASD. Epidural steroid injections reduce radicular inflammation in the short term.

Biologic disc repair for annular-tear–driven ASD: When imaging identifies an annular tear at the adjacent level as a driver of pain — with nucleus pulposus pressure provoking inflammatory mediators — intra-annular fibrin injection addresses the structural component directly. The fibrin sealant occludes the annular disruption, reducing nuclear material contact with pain-sensing nociceptors in the annular wall and surrounding structures. In published fibrin injection studies, VAS pain scores dropped from a baseline mean of 72.4 mm to 33.0 mm at 104 weeks — a clinically meaningful reduction. Separately, 80% of failed-back-surgery patients — a category that includes many post-fusion ASD patients — reported positive outcomes with fibrin injection. This approach is a bridge intervention: it addresses the disc-level pathology before another fusion resets the biomechanical cycle one level higher.

For patients weighing their options, our full comparison is here: Adjacent Segment Disease Fibrin Case Study — including outcome data from a post-fusion ASD patient treated with annular tear repair.

Extension fusion (last resort): When conservative and biologic approaches have been exhausted and the adjacent level has progressed to instability, severe stenosis, or structural failure, extension of the fusion construct is the definitive surgical treatment. This is not a failure of care — for the right patient at the right stage, it is the correct intervention. The goal of prior steps is to ensure that surgery is reserved for patients who truly require it.

If you are evaluating whether fusion is appropriate for your situation, see Spinal Fusion Candidate Criteria FAQ for a structured breakdown of the clinical criteria surgeons use.

Related Terms

• Pseudarthrosis: Failed fusion (non-union of bone graft), which increases mechanical stress across the construct and may contribute to adjacent-level overloading.
• Transitional syndrome: An older term for the same phenomenon — the transition zone between fused and mobile spine becomes a stress concentration point.
• Failed back surgery syndrome (FBSS): A broader category of persistent or recurrent pain after spinal surgery; ASD is one identifiable cause within FBSS.
• Proximal junctional kyphosis (PJK): A specific form of adjacent segment failure seen more often in long thoracolumbar fusion constructs, where the segment above the fusion develops kyphotic collapse.
• Annular tear: A disruption in the fibrous outer wall of the intervertebral disc; when present at an adjacent level, it is both a driver of ASD pain and a potential target for fibrin disc treatment.

Common Misconceptions About Adjacent Segment Disease

Misconception 1: “ASD means my original fusion failed.”
ASD does not mean the fusion itself failed technically. The fusion is usually solid — the hardware and bone graft are doing their job. ASD is a consequence of the mechanics of fusion, not a complication of surgical error in most cases.

Misconception 2: “More surgery is the only option.”
Extension fusion is one option at the end of the treatment continuum — not the starting point. Conservative care and, where appropriate, biologic disc repair address many patients at earlier stages of adjacent segment degeneration. The signs that you can avoid spine surgery resource outlines when structural and conservative approaches are sufficient.

Misconception 3: “Imaging determines whether I need surgery.”
Radiographic adjacent-level changes on MRI are common post-fusion and do not in themselves indicate that surgery is needed. Treatment decisions are based on the clinical correlation between imaging findings and symptoms — not on imaging alone.

Misconception 4: “ASD will keep progressing no matter what I do.”
ASD progresses more slowly in patients who remain active, maintain core strength, and manage body weight. The mechanical load environment of the spine is modifiable. Conservative and biologic interventions change the trajectory in many patients.

Frequently Asked Questions About Adjacent Segment Disease

How common is adjacent segment disease after spinal fusion?

Radiographic adjacent-segment changes are found in a significant proportion of fusion patients on follow-up imaging — some studies report rates above 30% within 5 years. Symptomatic ASD — actual clinical disease requiring intervention — affects a smaller subset. The 10-year revision rate for lumbar fusion exceeds 20%, and adjacent segment pathology accounts for a meaningful share of those reoperations. Risk varies with fusion length, patient age, adjacent-level health before surgery, and postoperative rehabilitation.

Can adjacent segment disease be treated without another surgery?

Yes, for many patients at the disc-based pain stage. Conservative care — physical therapy, core stabilization, anti-inflammatory management — reduces symptoms and slows progression in patients with mild to moderate ASD. When an annular tear at the adjacent level is identified as the structural driver of pain, intra-annular fibrin injection (biologic disc repair) directly addresses that pathology without reoperation. Surgical extension of the fusion construct is appropriate when these approaches no longer provide adequate function, or when instability, severe stenosis, or structural failure is documented.

What is the difference between adjacent segment disease and adjacent segment degeneration?

Adjacent segment degeneration (ASDeg) is a radiographic finding — disc height loss, signal changes, or facet arthrosis visible on imaging that is not producing symptoms. Adjacent segment disease (ASD) is the symptomatic form: the same structural changes accompanied by new or worsening clinical pain, radiculopathy, or neurological deficit. The distinction is clinically important because many post-fusion patients have some radiographic degeneration at adjacent levels that does not require treatment. Management decisions are based on symptomatic ASD, not on imaging findings alone.

How long after spinal fusion does adjacent segment disease typically appear?

Symptomatic ASD most commonly presents 5–10 years after lumbar fusion, though cases appear earlier in patients with pre-existing adjacent-level degeneration at the time of surgery. The process begins immediately with the biomechanical stress transfer that occurs after fusion, but the structural changes accumulate over years before producing symptoms. Patients with long fusion constructs, pre-operative adjacent-level disc changes, or poor sagittal alignment after surgery tend to develop symptoms on the earlier end of this range.

Is biologic disc repair an option for adjacent segment disease?

For patients in whom imaging identifies an annular tear at the adjacent level as a primary pain generator — evidenced by a high-intensity zone on MRI or provocation discography — intra-annular fibrin injection targets the structural disruption directly. Published research documents VAS pain scores improving from 72.4 mm at baseline to 33.0 mm at 104 weeks in fibrin injection patients. This makes annular tear repair a viable structural option for disc-based ASD pain before extension fusion is considered. Patient selection is critical: facet-dominant pain or instability-driven ASD requires different management. See our comparison of PRP vs. fibrin injection for non-surgical spine care for a side-by-side evidence review.

Sources & Further Reading

1. Park P, Garton HJ, Gala VC, Hoff JT, McGillicuddy JE. Adjacent segment disease after lumbar or lumbosacral fusion: review of the literature. Spine. 2004;29(17):1938–1944.
2. Hilibrand AS, Robbins M. Adjacent segment degeneration and adjacent segment disease: the consequences of spinal fusion? Spine Journal. 2004;4(6 Suppl):190S–194S.
3. Lawrence BD, Wang J, Arnold PM, et al. Predicting the risk of adjacent segment pathology after cervical arthroplasty: a systematic review. Spine. 2012;37(22 Suppl):S52–S58.
4. Maragkos GA, Tsitsopoulos PP. Current trends in lumbar fusion surgery and complications. International Journal of Spine Surgery. 2020;14(S1):S1–S8.
5. Finnoff JT, Fowler J, Lai J. A systematic review of lumbar spine biologic injection therapies. PM&R. 2019;11(9):972–980.
6. Martin BI, Mirza SK, Comstock BA, Gray DT, Kreuter W, Deyo RA. Reoperation rates following lumbar spine surgery and the influence of spinal fusion procedures. Spine. 2007;32(3):382–387.